RNAO+Aptamers the same as mRNA?
RNA Origami (RNAO) is not mRNA. Both are produced on the same equipment at scale. But where mRNA carries genetic instructions that direct a cell to produce a specific protein, RNAO carries no genetic information, does not modify gene expression, and does not enter the nucleus.
​
RNAO is a structural scaffold: a precisely folded molecule that optimally positions aptamers to bind their target. No gene therapy. No cellular reprogramming. Fully synthetic, derived from no biological source.
.jpg)
35x
30x
25x
20x
15x
10x
5x
0
Buffer
Apt 1
Apt 2
Linked
Apt 1 + 2
Origami
Platform
RNAO + Apatmers
Efficacy
Helixomer's Solution:
Unleashing the Promise of Aptamers
Polyethylene glycol (PEG) added to aptamers does extend the time to clearance, but anti-PEG antibodies are present in up to 70 percent of the population. Immune reactions to PEG have ended and paused multiple programs, and PEG does not improve binding efficacy.
​
Helixomer's RNA Origami (RNAO) folds multiple aptamers into a 3D architecture that improves binding efficacy, evades kidney clearance without PEG, and maintains a non-immunogenic profile with no animal-derived components.
​
Hex01 achieved a half-life of 2 to 3.5 hours in preclinical rabbit studies, is shelf-stable at room temperature for more than 15 months, and is manufactured on the same equipment as mRNA therapeutics.
Unleashing Aptamer Therapeutics with
RNA Origami (RNAO)
What are aptamers?
Aptamers are small, lab-made nucleic acids that bind with precision to a specific target (e.g., peptides, proteins, enzymes, or cells) without triggering an immune response. Unlike antibodies, which are protein-based and produced in biological systems, aptamers are fully synthetic and not animal-dependent.
​
Researchers have studied aptamers since 1990, but only two have reached FDA approval (Macugen, 2004; Izervay, 2023). The primary barriers have been rapid clearance from the body and insufficient binding strength. Helixomer's RNA Origami is designed to solve both.
Why Have Aptamers on RNAO?
Aptamers vs. Antibodies
​
